SEC digs into Pfizer's overseas profits, tax reductions
This article was originally published in Scrip
Pfizer had some "splainin' to do" when the Securities & Exchange Commission (SEC) said the pharma giant's reported domestic operations pre-tax losses of $2.2 billion in the US in 2011, with international operations producing pre-tax earnings of $15 billion, didn't quite jibe with what the firm reported for domestic and international revenues, which that year were $26.9 billion and $40.5 billion, respectively.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.